Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma
| Autor: | Lalitha Biswas, Pradeep Jacob, Misha J. C. Babu, Riju R. Menon, C. Gopalakrishnan Nair, A K Revathy, Krishnanunni Nair |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
endocrine system diseases
Endocrinology Diabetes and Metabolism BRAF V600E Mutation Analysis differentiated thyroid cancer 030209 endocrinology & metabolism lcsh:Diseases of the endocrine glands. Clinical endocrinology Papillary thyroid cancer Thyroid carcinoma 03 medical and health sciences Exon B-type Raf kinase V600E mutation 0302 clinical medicine Endocrinology Follicular phase Medicine papillary thyroid cancer lcsh:RC799-869 Pathological lcsh:RC648-665 business.industry medicine.disease genetic features of thyroid cancer 030220 oncology & carcinogenesis Mutation (genetic algorithm) Cancer research Original Article lcsh:Diseases of the digestive system. Gastroenterology business V600E |
| Zdroj: | Indian Journal of Endocrinology and Metabolism, Vol 21, Iss 2, Pp 329-333 (2017) Indian Journal of Endocrinology and Metabolism |
| ISSN: | 2230-8210 |
| Popis: | Introduction: Somatic B-type Raf kinase (BRAF) V600E mutation in exon 15 was frequently found in high frequencies associated with papillary thyroid cancer (PTC). The phenotype of these cancers expressed aggressive clinical and pathological features. The present study aimed to assess the prevalence of BRAF V600E mutation among conventional and follicular variants of PTC and its association with aggressive tumor factors and outcome. Study Design: Patients who were operated and received further treatment for PTC during 2012 were included in the study. BRAF V600E mutation analysis was done by extracting genomic DNA from tumor tissue. Results: Of the 59 patients included in the study, 51% harbored BRAF V600E mutation, but the mutation status was not associated with aggressive tumor factors and adverse outcome. Conclusion: BRAF V600E mutation was not significant predictor of aggressive tumor behavior in conventional and follicular variants of PTC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|